Search results
Showing 616 to 630 of 795 results for mental health
Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.
are in evidence review F: interventions to promote physical, mental, and emotional health and wellbeing of looked-after...
Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)
Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.
Show all sections
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)
Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.
Bipolar, schizophrenia and other psychoses: lithium levels in therapeutic range (IND87)
This indicator covers the percentage of patients on lithium therapy with a record of lithium levels in the therapeutic range within the previous 4 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM22
Bipolar, schizophrenia and other psychoses: target organ damage (IND86)
This indicator covers the percentage of patients on lithium therapy with a record of serum creatinine and TSH in the preceding 9 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM21
Alcohol use: brief intervention for people with SMI (IND200)
This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses with a FAST score of 3 or more or AUDIT-C score of 5 or more in the preceding 12 months who have received a brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM179
This indicator covers establishing and maintaining a register of all patients on the autistic spectrum. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM153
Bipolar, schizophrenia and other psychoses: annual blood glucose or HbA1c (IND159)
This indicator covers the percentage of patients aged 18 years and over with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood glucose or HbA1c in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM130
Bipolar, schizophrenia and other psychoses: annual cholesterol (IND158)
This indicator covers the percentage of patients aged 18 years and over with schizophrenia, bipolar affective disorder and other psychoses who have a record of total cholesterol: hdl ratio in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM129
Smoking: support and treatment for people with bipolar, schizophrenia and other psychoses (IND155)
This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder or other psychoses who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM125
Smoking: smoking status of people with bipolar, schizophrenia and other psychoses (IND154)
This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM124
This indicator covers the proportion of people treated by Improving Access to Psychological Therapies (IAPT) for anxiety disorders who return to full function. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG54
Depression and anxiety: recovery following talking therapies (IND26)
This indicator covers the proportion of people of all ages with depression and anxiety who clinically recover following talking therapies. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG41
Bipolar, schizophrenia and other psychoses: register (IND257)
This indicator covers the contractor establishing and maintaining a register of patients with schizophrenia, bipolar affective disorder and other psychoses. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM241